Drug Profile
H3N2 M2SR influenza vaccine - FluGen
Alternative Names: H3N2 vaccine - FluGen; H3N2-M2SR; Influenza A virus vaccine H3N2-FluGen; Redee Flu; RedeeFlu; Sing2016 M2SR H3N2 influenza vaccineLatest Information Update: 14 Nov 2022
Price :
$50
*
At a glance
- Originator FluGen
- Developer FluGen; National Institute of Allergy and Infectious Diseases
- Class Influenza A vaccines; Synthetic vaccines; Vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza A virus H3N2 subtype
Most Recent Events
- 09 Nov 2022 Immunogenicity data from a phase I trial in Influenza A virus H3N2 subtype released by FluGen
- 03 Nov 2022 FluGen completes a Phase I trial in Influenza A virus H3N2 subtype (In volunteers, In the elderly) in USA (Intranasal) (NCT05163847)
- 14 Jun 2022 Phase-I clinical trials in Influenza A virus H3N2 subtype (In volunteers, In the elderly) in USA (Intranasal) (NCT05163847)